Restriction fragment length polymorphism of the L-myc gene in oral cancer patients

Saranath, Dhananjaya; Panchal, Rekha G.; Nair, Rama C.; Mehta, A. R.; Sanghavi, Vikram; Deo, M. G.

doi:10.1038/bjc.1990.119

Cited by 40 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scattered reports have suggested that individuals bearing the`short' (S) allele either have an increased incidence of certain tumors and/or that such tumors manifest a more aggressive behavior. The associated neoplasms include soft-tissue sarcomas (Kato et al, 1990), oral cancers (Saranath et al, 1990), colorectal cancers (Young et al, 1994), nonHodgkin's lymphoma (Crossen et al, 1994), breast cancer (Champeme et al, 1992), and non-SCLC lung cancer (Kawashima et al, 1988). In contrast, at least one report has suggested that the`SS' genotype protects against hepatocellular cancer (Taylor et al, 1993).…”

Section: Small Cell Lung Cancer (Sclc)mentioning

confidence: 99%

MYC oncogenes and human neoplastic disease

1999

View full text Add to dashboard Cite

c-myc, N-myc and L-myc are the three members of the myc oncoprotein family whose role in the pathogenesis of many human neoplastic diseases has received wide empirical support. In this review, we ®rst summarize data, derived mainly from non-clinical studies, indicating that these oncoproteins actually serve quite di erent roles in vivo. This concept necessarily lies at the heart of the basis for the observation that the deregulated expression of each MYC gene is reproducibly associated with only certain naturally occurring malignancies in humans and that these genes are not interchangeable with respect to their aberrant functional consequences. We also review evidence implicating each of the above MYC genes in speci®c neoplastic diseases and have attempted to identify unresolved questions which deserve further basic or clinical investigation. We have made every attempt to review those diseases for which signi®cant and con®rmatory evidence, based on studies with primary tumor material, exists to implicate MYC members in their causation and/or progression.

show abstract

Section: Small Cell Lung Cancer (Sclc)mentioning

confidence: 99%

MYC oncogenes and human neoplastic disease

1999

View full text Add to dashboard Cite

show abstract

“…Recently, several oncogenes previously shown to be involved in various human malignancies (Klein & Klein, 1985;Yokota et al, 1986), have been implicated in oral cancers (Field & Spandidos, 1987;Hoellering & Shuler, 1988;Saranath et al, 1989;Saranath et al, 1990). In the Indian cases of oral SCCs examined by Saranath and co-workers (1989), a 5-to 10-fold amplification of one or more of the c-myc, N-myc, K-ras and N-ras oncogenes was observed in 13/23 (56%) of the tumour samples.…”

mentioning

confidence: 99%

“…Neither L-myc nor H-ras were amplified in the SCCs. Further, studies on restriction fragment length polymorphism (RFLP) with respect to L-myc in oral cancer patients demonstrated the S allele (6.6kb EcoRI fragment) predominating in poor to moderately differentiated tumours, as well as larger sized tumours (Saranath et al, 1990).…”

mentioning

confidence: 99%

High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India

Saranath¹,

Chang²,

Bhoite³

et al. 1991

Br J Cancer

Self Cite

223

120

View full text Add to dashboard Cite

show abstract

“…Several studies of cancers other than lung in non-Japanese populations have also linked the S allele with tumour progression. The S allele was associated with tumour size and a lack of differentiation in Indian oral cancer patients (Saranath et al, 1990), and lung metastases in Caucasian breast cancer patients (Champeme et al, 1992). Furthermore, the SS genotype was associated with a worsening clinicopathological stage in Australian colorectal patients recruited from the same region in Queensland as our cases (Young et al, 1994).…”

mentioning

confidence: 99%

MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer

Fong

Kida²,

Zimmerman³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary Some studies have suggested that the S allele of the MYCL oncogene, which results from an intragenic EcoRI restriction fragment length polymorphism (RFLP), may be associated with cancer susceptibility. In addition, this allele has also been linked to metastases and adverse survival in certain cancers, although studies of lung cancer patients from different populations have yielded controversial results. We studied 108 cases of surgical resected non-small-cell lung cancer (NSCLC) and found no evidence that MYCL gentotypes were associated with tumour progression or a worse prognosis. However, the presence of loss of heterozygosity (LOH) In terms of cancer susceptibility, the S allele of MYCL was more common in patients with non-Hodgkin's lymphoma (Crossen et al., 1994), and male patients with bone and softtissue sarcomas . In addition, the SS genotype was more frequent in colorectal cancer patients than in young blood donor controls (Young et al., 1994). However, the cancer-susceptibility model is controversial, as the SS genotype appears to protect against hepatocellular cancer (Taylor et al., 1993), and the S allele was not increased in patients with lung cancer (Tamai et al., 1990;Weston et al., 1992Weston et al., , 1994, breast cancer (Champeme et al., 1992) or lymphoma/leukaemia (Chenevix-Trench et al., 1989).As regards tumour progression, Kawashima et al. (1988, 1992), in an initial study followed by a larger study involving 252 Japanese lung cancer patients, showed that the S allele predisposed to metastases and adverse prognosis. Conversely, this association has not been found in Caucasian (Norwegian and North American) lung cancer populations (Tamai et al., 1990;Tefre et al., 1990;Weston et al., 1992Weston et al., , 1994. While the conflicting results may have been owing to racial/ethnic differences, there were also significant methodological variations between the studies, such as case stratification, including heterogeneity in the subtypes of lung cancer, disease stage and treatment modalities; all factors which are known to affect tumour progression and outcome.To address some of these possible confounders, we investigated the relationship of MYCL genotypes to tumour stage, nodal metastases and survival in a well-defined, homogeneous lung cancer subset; histologically diagnosed NSCLC patients who had curative surgery as their primary treatment and who had. comprehensive post-surgical staging and follow-up. Materials and methodsDNA was obtained from 108 cases of post-surgically staged, resected NSCLC and normal lung tissue from patients at The Prince Charles Hospital, Brisbane, Australia as previously described (Fong et al., 1995).The MYCL gene was discovered as two additional DNA fragments of 10.0 kb and 6.6 kb when the MYC gene was used to probe EcoRI digested human genomic DNA (Nau et al., 1985). These fragments represent a RFLP at the MYCL locus, situated in the second intron (Kaye et al., 1988). This RFLP can also be revealed with polymerase chain reaction (PCR) using primers, which fla...

show abstract

Restriction fragment length polymorphism of the L-myc gene in oral cancer patients

Cited by 40 publications

References 17 publications

MYC oncogenes and human neoplastic disease

MYC oncogenes and human neoplastic disease

High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India

MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer

Contact Info

Product

Resources

About